ChromaDex Corp. (NASDAQ:CDXC), an innovator of science-based,
proprietary health and wellness consumer products and ingredient
technologies that promote health longevity announced today its new
partnership with Hong Kong based retailer, A.S. Watson, for the
launch of the U.S. made TRU NIAGEN™ dietary supplement
(www.truniagen.com) in Asia.
With over 6,000 stores in 11 Asian and European
markets, Watsons is the leading health and beauty retailer in Asia
and Europe. On September 15, Watsons will launch TRU NIAGEN™
in over 100 stores in Hong Kong and online in eStore at
www.watsons.com.hk.
Frank Jaksch, Jr., CEO and Co-founder of
ChromaDex stated, “We’re excited to have a premier partner in
Watsons, for the launch of TRU NIAGEN™ in Asia. They are globally
renowned for offering a market-leading product range, and
exceptional personalized consultation to educate their
consumers.”
Ms. Diane Cheung, General Manager of Watsons
Hong Kong shared, “Our innovative consumers are looking for
nutritional support to help them age better. Watsons prides
itself on bringing breakthrough health and nutrition technologies
to its consumers. TRU NIAGEN™ is a proven, safe and effective
way to significantly boost NAD+, which may help our consumers
achieve health longevity.”
NAD+ plays an essential role in cellular
metabolism and maintaining healthy cellular function. Published
research suggests that declines in NAD+ are linked to a variety of
challenges associated with aging.
Robert Fried, President, and Chief Strategy
Officer of ChromaDex, added, “This critical milestone is the first
step in executing our broader expansion plans for TRU NIAGEN™. With
the science continually reinforcing just how important NAD+ and
this nutrient are to health, we recognize our responsibility to
distribute it widely, safely and with the finest partners around
the globe.”
Soon after the premiere in Hong Kong, Watsons
plans to launch TRU NIAGEN™ in additional retail outlets in Macau
and in other Asian countries in the near future. TRU NIAGEN™ will
be available with a single bottle priced at HK$388. Annual
subscriptions and multi bottle packs will also be offered online
soon.
To date, ChromaDex has invested millions in
analytical research, toxicology studies and human clinical trials
supporting the safety and efficacy of TRU NIAGEN™. It has
initiated over 120 collaborative studies with leading universities
and research institutions such as the National Institute of Aging,
MIT and the Scripps Research Institute, representing an estimated
$50+ million in additional nicotinamide riboside
research.
For more information on ChromaDex, visit:
https://www.chromadex.com/.
About NAD+NAD+ activates
cellular metabolism and energy production within the cell’s “power
stations,” the mitochondria. Our mitochondria are constantly
working to convert the food we eat into the energy necessary to
power all bodily systems as well as help us stay healthy. The
challenge is that both NAD+ levels and mitochondrial functions
decline as we age. This reduction in NAD+ is believed by scientists
to be linked to a wide variety of age-related challenges.
About TRU NIAGEN™ TRU NIAGEN™
is a branded dietary supplement brought to market by key
nicotinamide riboside innovator and patent holder, ChromaDex.
NIAGEN® nicotinamide riboside (NR), also supplied by ChromaDex, is
the feature ingredient in TRU NIAGEN™. Research published in
Nature Communications demonstrates it is clinically proven to boost
NAD+ (nicotinamide adenine dinucleotide) levels, which decline with
age. Only NIAGEN® nicotinamide riboside has Generally Recognized as
Safe (GRAS) status and a New Dietary Ingredient Notification
(NDIN), both reviewed by FDA.
About ChromaDex:ChromaDex
leverages its complementary business units to discover, acquire,
develop and commercialize patented and proprietary health and
wellness consumer products and nutritional ingredient technologies
that promote healthy longevity. In addition to our consumer product
and ingredient technologies units, we also have business units
focused on natural product fine chemicals (known as
"phytochemicals"), and product regulatory and safety consulting. As
a result of our relationships with leading universities and
research institutions, we are able to discover and license early
stage, IP-backed ingredient technologies. We then utilize our
in-house chemistry, regulatory and safety consulting business units
to develop commercially viable ingredients. Our consumer product
and ingredient portfolio are backed with clinical and scientific
research, as well as extensive IP protection. Our portfolio of
patented ingredient technologies includes NIAGEN® nicotinamide
riboside; pTeroPure® pterostilbene; PURENERGY®, a
caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and
AnthOrigin®, anthocyanins derived from a domestically-produced,
water-extracted purple corn husk. To learn more about ChromaDex,
please visit www.ChromaDex.com.
About Watsons:Watsons is Asia’s
leading health and beauty retailer, currently operating over 6,000
stores – more than 1,500 of which are pharmacies, in 11 Asian and
European markets, including China (Mainland China, Hong Kong,
Taiwan and Macau), Singapore, Thailand, Malaysia, the Philippines,
Indonesia, Turkey and Ukraine. Watsons operates over 220 stores in
Hong Kong and Macau, of which over 50 have in-store pharmacies,
making Watsons the No. 1 Pharmacy Network in Hong Kong.
Watsons has a professional team of pharmacists,
dieticians, Chinese medicine practitioners, health & fitness
advisors, beauty consultants, an experienced mother & baby
advisor and a nurse. They are devoted to serving customers, and
offer the longest pharmacy operating hours in Hong Kong.
Watsons continually sets the highest standards
in the health, wellness and beauty market, providing personalized
advice and counseling in health, beauty and personal care on top of
its market-leading product range, making customers LOOK GOOD, FEEL
GREAT every day. Since 2009, Watsons has been the No. 1 Pharmacy/
Drugstore brand in Asia*. In Europe, Watsons is also the leading
Health & Beauty retailer in Ukraine.
*Campaign Asia-Pacific/ Nielsen’s “Asia's Top
1,000 Brands” Online Study 2017 of over 6,000 respondents across 13
markets in Asia Pacific region
About A.S. Watson
Group:Established in Hong Kong in 1841, A.S. Watson Group
is the largest international health and beauty retailer in Asia and
Europe with over 13,500 stores in 24 markets. Each year, over three
billion customers and members shop with A.S. Watson’s 13 retail
brands, both in stores and online.
In Hong Kong, A.S. Watson operates more than 600
stores under four retail brands – Watsons, PARKnSHOP, FORTRESS, and
Watson’s Wine. In addition, A.S. Watson manufactures and
distributes high quality drinking water brand Watsons Water, as
well as the famous juice drinks Mr. Juicy and Sunkist.
For the fiscal year 2016, A.S. Watson Group
recorded revenue of HKD151.5 billion. A.S. Watson has over 130,000
employees worldwide, including 12,900 in Hong Kong.
A.S. Watson Group is also a member of the
world-renowned multinational conglomerate CK Hutchison Holdings
Limited, which has five core businesses ‐ ports and related
services, retail, infrastructure, energy and telecommunications in
over 50 countries.
Please visit www.aswatson.com for more in-depth
information about A.S. Watson Group and its brands. You may also
stay in touch with A.S. Watson via its digital presence (eCommerce,
social media, mobile app & more); more details are at
http://www.aswatson.com/our-customers/digitalasw/.
Forward-Looking Statements:This
release contains forward-looking statements relating to ChromaDex
and ChromaDex’s business within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities and Exchange Act of 1934, as amended, including
statements related to the timing and expansion plans of launching
TRU NIAGEN™ in Asia, the ability of ChromaDex to execute on
expanding TRU NIAGEN™ sales, whether science will reinforce how
important NAD+ and TRU NIAGEN™ are to health, the health benefits
of TRU NIAGEN™, including whether TRU NIAGEN™ can help consumers
achieve health longevity, the amount ChromaDex will invest in
trials supporting the safety and efficacy of TRU NIAGEN™, the price
of TRU NIAGEN™ to consumers in Asia and whether a reduction in NAD+
is linked to age-related challenges. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects", "anticipates", "intends", "estimates",
"plans", "potential", "possible", "probable", "believes", "seeks",
"may", "will", "should", "could" or the negative of such terms or
other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2016,
ChromaDex's Quarterly Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024